P01.129 Cost-effectiveness of [18F] FET for therapy assessment of temozolomide for patients with glioblastoma in a Belgian healthcare setting

BACKGROUND: Temozolomide has been approved for the treatment of glioblastoma by the FDA in 2005 and became the standard of care very fast. However, more than 50% of the patients treated with temozolomide do not show any clinical response. MRI forms the main imaging modality to assess the therapy eff...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neuro Oncol
Main Authors: Baguet, T, Verhoeven, J, de Vos, F, Goethals, I
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2018
Fag:
Poster Presentations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144657/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.171
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker